Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

CARES Act and Public Health Emergency Funds Allocation

The Department of Health and Human Services (HHS) announced how it plans to allocate the…

read more

CARES Act Provider Relief Fund Additional Information

AMA Updates on CARES Act Today the Department of Health and Human Services (HHS) provided…

read more

Interim Package and Resuming Non-COVID Care

Sharing the latest on the interim package and the news from CMS about resuming non-COVID…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/15/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/26/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course Learn more

07/15/20: Call for Scientific Papers
Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

12/01/20: Research Grant Cycle
Learn more

EDUCATION

New Virtual Course!

Register now as we build out Part 2 Core Allergy & Part 3 Core Rhinology.   Both promise to deliver clinical content you need.  Core Allergy will offer what you need to help refresh or add allergy to your practice — everything from the clinical science to the basics of allergy from a better understanding of testing techniques, vial prep, and dose calculations to other practical implications.  Core Rhinology encompassed the highly sought after rhinology content from our former IAR program.  Part 1 will launch soon with on demand content to help you balance all your time demands.  Part 2 & 3 will feature live-stream content to give you opportunities to interact with the faculty.  Post live session, this content will also be available on demand. Stay tuned for more details as we finish our program build. Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

NEW VIRTUAL COURSE! Core Allergy and Rhinology Concepts: Age of Pandemics and Beyond
Learn How to Reboot Your Practice and Freshen Up on Core Allergy and Rhinology Components
Learn More and Register

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
COVID-19 has made it impossible to convene our 2020 Basic Course. We hope you will consider another AAOA CME opportunity

2020 AAOA Annual Meeting
October 23-25| Scottsdale, AZ
Learn More and Register

2020 Advanced Course in Allergy & Immunology
December 9-12 | Vail, CO
Learn More and Register

AAOA Clinical Insights
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 Basic Course in Allergy & Immunology
July 15-17 | Seattle, WA

News and Updates

Resuming SCIT During COVID-19 Pandemic

This summary is intended to provide practicing Otolaryngologists a guide to resuming safe allergy care…

read more

Small Business Paycheck Protection Program

by Dole Baker, MD, FAAOA, AAOA Socioeconomic Committee Member  Small Business Paycheck Protection Program is…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Menu
AAOA Logo

Practice Resources

Compounding Updates

vials of allergens

As we continue to monitor activity both at the FDA and USP in relation to physician compounding, we wanted to offer the latest update.

USP: To provide a unified approach to quality compounding, USP is aligning the timing and content of General Chapters <795>, <797>, and <800>. Chapter <797> Pharmaceutical Compounding – Sterile Preparations is the chapter relating to allergy immunotherapy. Below is the current proposed timeline and web links for use during the public comment periods. AAOA will continue to monitor the progress and alert you when the revised version of <797> is released for comment.

Schedule & Links for Compounding Standards

Click the links for access where the respective information will be posted (Active after 2/28/2018)

 

 

 

<795>*

Pharmaceutical Compounding‒ Nonsterile Preparations

<797>*

Pharmaceutical Compounding Sterile Preparations

Pre-Posted on the USP Website for Public Comment**

 

 March 30, 2018 July 28, 2018
Published in the Pharmacopeial Forum

 

 May 1, 2018 September 4, 2018
Open Microphone Session

Registration will open

 April 20, 2018

 

 March 15, 2018

 

September 5, 2018

 

 August 5, 2018

 

Public Comment Period will close

 

 July 31, 2018

 

November 30, 2018
Intended Publication DateUSP – NF

 

 June 1, 2019

 

June 1, 2019
Anticipated Official Date

 

 December 1, 2019 December 1, 2019

*   The current published versions of USP-NF General Chapters <795> and <797> are official until new chapters become official.

** This pre-posting allows extra time, beyond the typical 90 day period, for stakeholders to review and provide input.

FDA: This morning the FDA held a stakeholder teleconference regarding its final guidance on compounded drug products.  The links below provide the summaries. FDA recognizes that compounded drugs play an important healthcare role for certain patients for whom FDA-approved drugs are not available, as well as the increased risk associated with compounding. As such, this guidance is intended to help reduce that risk.

The final guidance documents that we will discuss are:

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf

Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510153.pdf

For additional information please visit FDA’s website: https://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/

FDA Approval Updates

The U.S. Food and Drug Administration (FDA) recently approved the following sublingual tablets for pollen-induced allergies:

Merck’s RAGWITEK(TM), a sublingual immunotherapy tablet for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for short ragweed pollen. The complete press release from Merck is available:RAGWITEK.

Greer’s ORALAIR(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for any of the five grass species contained in the product (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass). The complete press release from Greer is available:ORALAIR.

Merck’s GRASTEK(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for Timothy Grass or cross-reactive grass pollens. The complete press release from Merck is available:<a “href=”https://www.aaoallergy.org/wp-content/uploads/2017/05/GRASTEK-press-release.pdf”>GRASTEK.

A Member Benefit

Allergy and Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

News

New Articles from IFAR

Medical therapy for Chronic Rhino-sinusitis

The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined..
Read More

Safety of long-term Intranasal Budesonide

The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP).. Read More

President Mims Message

April 2017

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices. Read More